In the CATT [14], serious ocular adverse effects rates reported with intravitreal anti-VEGF were: endophthalmitis (ranibizumab: ≤0.7%, bevacizumab: ≤1.4%), uveitis (ranibizumab: ≤0.3%, bevacizumab: ≤0.7%), retinal/choroidal detachment (ranibizumab: 0.0%, bevacizumab: ≤1.0%), retinal tear (ranibizumab: ≤0.3%, bevacizumab: ≤0.3%), ocular vessel embolism or occlusion (ranibizumab: ≤0.7%, bevacizumab: ≤0.7%) and vitreous haemorrhage (ranibizumab: ≤0.3%, bevacizumab: ≤0.3%) both for the monthly and as needed scheme (Table 4). Here, VEGFA is linked to optic choroid disorder.